An interventional study of Melatonin 1mg and intravenous B-complex vitamin drip and Placebo in Fibromyalgia, sponsored by University of Thessaly. Recruiting at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by University of Thessaly · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Fibromyalgia (FMS) is characterized by chronic musculoskeletal pain, sleep disturbances, and fatigue. It is not entirely clear how Bcomplex vitamins affect the human pain system, while at the same time there have been approaches that use melatonin in patients with FMS and report improvements in pain and sleep quality.
The purpose of this study is to investigate the efficacy of a combined immunonutrition and melatonin intervention in patients with FMS through a randomized clinical trial (RCT). The combined effect of immunonutrition and melatonin, administered intravenously once a week and orally respectively, versus placebo, will be examined in patients with FMS, for a period of 5 weeks. The primary endpoints concern the quantification of pain and quality of life, while the secondary endpoints are sleep quality, fatigue and inflammatory markers.
Recent data have shown the potential role of melatonin as an adjuvant treatment in fibromyalgia (FMS), as it appears to improve sleep quality, reduce pain, and improve patient- and physician-reported assessments of quality of life. In addition to melatonin, intravenous micronutrient therapy has also been reported to improve symptoms in patients with fibromyalgia. More specifically, the intravenous administration of a mixture of vitamins and trace elements has been associated with reductions in pain, fatigue, and the number of tender points, as well as improvements in mood, quality of life, and energy levels for daily activities in patients with FM. Following a review of the available literature, a randomized, placebo-controlled clinical trial will be conducted to evaluate the efficacy of the combined administration of melatonin and intravenous vitamin drip in patients with FMS compared with a control group receiving placebo.
The primary outcomes will include changes in pain and quality of life, assessed using the following validated instruments: the Visual Analogue Scale (VAS), the Revised Fibromyalgia Impact Questionnaire (FIQR), the Functional Assessment of Chronic Illness Therapy (FACIT), and the Brief Pain Inventory (BPI). Additional primary outcome measures will include the patient's subjective perception of change, assessed using the Patient Global Impression of Change (PGIC), and the degree of central sensitization, assessed using the Central Sensitization Inventory (CSI).
The secondary outcomes will include changes in sleep-related symptoms, assessed using the Epworth Sleepiness Scale (ESS); changes in fatigue, assessed using the Fatigue Severity Scale (FSS); changes in psychological symptoms, assessed using the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI); and changes in inflammatory markers, specifically C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
This study's planned enrollment of 60 is close to the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Browse Fibromyalgia studies →University of Thessaly is the lead sponsor of 195 studies on the registry; 44 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult patients diagnosed with Fibromyalgia Speak and understand the Greek language Consent to participate
Exclusion Criteria:
Children and adolescents Diagnosed with other chronic pain disorders or disease Recent modification of their treatment (within 3 months) Pregnant and breastfeeding women Patients with severe renal or cardiac disease, cancer, infection, epilepsy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Per os Melatonin 1mg every night half an hour before sleep and intravenous B-complex vitamin drip every week
Dietary Supplement: Melatonin 1mg and intravenous B-complex vitamin drip
Per os corn startch placebo capsules every night half an hour before sleep and intravenous N/S 500mL drip every week
Dietary Supplement: Placebo
Drug page: MelatoninStudies of MelatoninMelatonin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients will receive Melatonin 1mg half an hour before sleep every day and intravenous B-complex vitamin drip every week for a total of five weeks
Per os corn startch placebo capsules every night half an hour before sleep and intravenous N/S 500mL drip every week
VAS pain
Pain on a scale from 0 to 10 where 0 indicates "no pain" and 10 indicates "the worst possible pain"
Time frame: 5 weeks
Brief Pain Inventory (BPI)
Time frame: 5 weeks
Revised Fibromyalgia Impact Questionnaire (FIQR)
Time frame: 5 weeks
Functional Assessment of Chronic Illness Therapy (FACIT)
Time frame: 5 weeks
Patient Global Impression of Change (PGIC)
Time frame: 5 weeks
Central Sensitization Inventory (CSI)
Time frame: 5 weeks
Epworth Sleepiness Scale (ESS)
Time frame: 5 weeks
Fatigue Severity Scale (FSS)
Time frame: 5 weeks
Inflammatory markers
CRP, ESR
Time frame: 5 weeks
Beck Depression Inventory (BDI)
Time frame: 5 weeks
Beck anxiety inventory (BAI)
Time frame: 5 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 12 months is below that.
Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Melatonin